jRCT2051200124已完成不适用
A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Subjects with HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 120
- 主要终点
- confirmed ORR by BICR
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Adults aged >=20 years in Japan, Taiwan, and Korea, or those aged >=18
- •years in other countries, at the time the Informed Consent Forms (ICFs)
- •are signed.
- •Pathologically-documented, unresectable, recurrent, or metastatic
- •colorectal adenocarcinoma. Participants must have BRAF wild-type
- •cancer and RAS status identified in primary or metastatic site.
- •The following therapies should be included in prior lines of therapy:
- •a. Fluoropyrimidine, oxaliplatin, and irinotecan, unlesscontraindicated
- •b. Anti-EGFR treatment, if RAS wild-type and if clinically indicated
- •c. Anti-VEGF treatment, if clinically indicated
- •d. Anti-PD-(L)-1 therapy, if tumor is MSI-high/deficient mismatch repair (dMMR), or tumor mutational burden (TMB)-high, if clinically indicated
- •Confirmed HER2-overexpressing status assessed by central laboratory
- •and defined as IHC 3+ or IHC 2+/ISH+.
- •Presence of at least one measurable lesion assessed by the Investigator
- •per RECIST version 1.
- •ECOG PS of 0 or
- •Has LVEF >=50% within 28 days before randomization/registration.
排除标准
- •Medical history of myocardial infarction (MI) within 6 months before randomization/registration, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV). Participants with troponin levels above ULN at Screening (as defined by the manufacturer), and without any MI-related symptoms, should have a cardiologic consultation before randomization/registration to rule out MI.
- •Has a corrected QT interval (QTcF) prolongation to >470 msec (female participants) or >450 msec (male participants) based on the average of the Screening triplicate 12-lead ECGs.
- •Has a history of (non-infectious) ILD/pneumonitis that required steroids,
- •has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
- •Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli within 3 months of the randomization/registration, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, pleural effusion, etc.).
- •Any autoimmune, connective tissue, or inflammatory disorders (eg, rheumatoid arthritis, Sjogren syndrome, sarcoidosis, etc.) where there is documented, or a suspicion of, pulmonary involvement at the time of Screening.
- •Prior pneumonectomy.
- •Has spinal cord compression or clinically active central nervous system
- •metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
- •Participants with clinically inactive brain metastases may be included in the study. Participants with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole-brain radiotherapy and randomization/registration.
- •Participants with leptomeningeal carcinomatosis.
- •Has known human immunodeficiency virus (HIV) infection.
- •Active hepatitis B and/or hepatitis C infection, such as those with
- •serologic evidence of viral infection within 28 days before study randomization/registration. Participants with past or resolved hepatitis B
- •virus (HBV) infection are eligible if hepatitis B surface antigen (HBsAg) negative (-) and antibody to hepatitis B core antigen (anti-HBc) positive (+).
- •Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- •Previous treatment with a DXd-containing ADC.
结局指标
主要结局
confirmed ORR by BICR
To assess the efficacy of trastuzumab deruxtecan (T-DXd), as measured by the confirmed ORR by BICR in HER2-overexpressing (defined as IHC 3+ or IHC2+/ISH+) mCRC subjects treated at the 5.4 mg/kg and 6.4 mg/kg doses
次要结局
- ORR
- DoR
- DCR
- CBR
- PFS
- OS
- Safety and tolerability
- HRQoL
- Symptoms
- Physical functioning
- Healthcare resource utilization
- PK
- Immunogenicity
研究者
相似试验
进行中（未招募）
不适用
Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or After a Trastuzumab-Containing RegimenjRCT2031200369DAIICHI SANKYO Co.,Ltd.490
已完成
不适用
Trastuzumab deruxtecan for subjects with HER2 mutated metastatic NSCLCNon-Small Cell Lung CancerjRCT2071220096DAIICHI SANKYO Co.,Ltd.30
进行中（未招募）
不适用
Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study - TRAIN studyHER2 positive breat cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2008-000987-18-NLetherlands Cancer Institute
已完成
不适用
Trastuzumab incombination with S-1/CDDP of HER2-positive advanced gastric cancer: a phase II trial.HER2 positive gastric cancerJPRN-UMIN000005792Dept. of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences30
已完成
2 期
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT04644237Daiichi Sankyo152